首页 > 最新文献

Advances in respiratory medicine最新文献

英文 中文
Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis 波兰呼吸学会诊断和治疗进行性纤维化间质肺疾病(非特发性肺纤维化)指南
IF 1.8 Q3 Medicine Pub Date : 2022-10-01 DOI: 10.3390/arm90050052
W. Piotrowski, M. Martusewicz-Boros, A. Białas, A. Barczyk, B. Batko, K. Błasińska, P. Boros, K. Górska, P. Grzanka, E. Jassem, D. Jastrzębski, Janina Kaczyńska, O. Kowal-Bielecka, E. Kucharz, J. Kuś, B. Kuźnar-Kamińska, B. Kwiatkowska, R. Langfort, K. Lewandowska, B. Maćkiewicz, S. Majewski, J. Makowska, J. Miłkowska-Dymanowska, E. Puścińska, A. Siemińska, M. Sobiecka, Renata Soroka-Dąda, M. Szołkowska, E. Wiatr, D. Ziora, P. Śliwiński
Highlights The working group of the Polish Respiratory Society (PTChP) developed guidelines for diagnosis and treatment of PF-ILD. What are the main findings? A multidisciplinary team should be involved in the diagnosis and treatment of progressive pulmonary fibrosis. Nintedanib alone or in combination with immunomodulatory drugs is recommended for the treatment of PF-ILD, especially when an earlier solely immunomodulatory treatment was ineffective. What are the implications of the main finding? This document is a guide for Polish medical personnel involved in the diagnosis and treatment of PF-ILD. The guidelines will serve as an aid for healthcare organizers in Poland on how to optimize the diagnostic and therapeutic processes for ILD and improve the access of patients to modern therapy. Abstract The recommendations were developed as answers to previously formulated questions concerning everyday diagnostic and therapeutic challenges. They were developed based on a review of the current literature using the GRADE methodology. The experts suggest that PF-ILD be diagnosed based on a combination of different criteria, such as the aggravation of symptoms, progression of radiological lesions, and worsening of lung function test parameters. The experts recommend a precise diagnosis of an underlying disease, with serological testing for an autoimmune disease always being included. The final diagnosis should be worked out by a multidisciplinary team (MDT). Patients with an interstitial lung disease other than IPF who do not meet the criteria for the progressive fibrosis phenotype should be monitored for progression, and those with systemic autoimmune diseases should be regularly monitored for signs of interstitial lung disease. In managing patients with interstitial lung disease associated with autoimmune diseases, an opinion of an MDT should be considered. Nintedanib rather than pirfenidon should be introduced in the event of the ineffectiveness of the therapy recommended for the treatment of the underlying disease, but in some instances, it is possible to start antifibrotic treatment without earlier immunomodulatory therapy. It is also admissible to use immunomodulatory and antifibrotic drugs simultaneously. No recommendations were made for or against termination of anti-fibrotic therapy in the case of noted progression during treatment of a PF-ILD other than IPF. The experts recommend that the same principles of non-pharmacological and palliative treatment and eligibility for lung transplantation should be applied to patients with an interstitial lung disease other than IPF with progressive fibrosis as in patients with IPF.
波兰呼吸学会(PTChP)工作组制定了PF-ILD的诊断和治疗指南。主要发现是什么?进行性肺纤维化的诊断和治疗应由多学科团队参与。尼达尼布单独或联合免疫调节药物被推荐用于治疗PF-ILD,特别是当早期单独免疫调节治疗无效时。主要发现的含义是什么?本文件是波兰医疗人员参与诊断和治疗PF-ILD的指南。该指南将为波兰的卫生保健组织者提供帮助,帮助他们优化ILD的诊断和治疗过程,并改善患者获得现代治疗的机会。这些建议是为了回答以前制定的关于日常诊断和治疗挑战的问题。它们是基于使用GRADE方法对当前文献的回顾而开发的。专家建议,PF-ILD的诊断应结合不同的标准,如症状的加重、放射学病变的进展和肺功能测试参数的恶化。专家们建议对潜在疾病进行精确诊断,同时对自身免疫性疾病进行血清学检测。最终诊断应由多学科小组(MDT)作出。对于不符合进行性纤维化表型标准的IPF以外的间质性肺病患者,应监测其进展情况,对于患有全身性自身免疫性疾病的患者,应定期监测间质性肺病的迹象。在管理与自身免疫性疾病相关的间质性肺疾病患者时,应考虑MDT的意见。如果推荐的治疗潜在疾病的方法无效,则应采用尼达尼布而不是吡非尼顿,但在某些情况下,可以在不进行早期免疫调节治疗的情况下开始抗纤维化治疗。同时使用免疫调节和抗纤维化药物也是允许的。在PF-ILD治疗期间除IPF外出现明显进展的情况下,没有建议支持或反对终止抗纤维化治疗。专家建议,非药物治疗和姑息治疗以及肺移植资格的原则应适用于除IPF患者外的间质性肺疾病伴进行性纤维化患者。
{"title":"Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis","authors":"W. Piotrowski, M. Martusewicz-Boros, A. Białas, A. Barczyk, B. Batko, K. Błasińska, P. Boros, K. Górska, P. Grzanka, E. Jassem, D. Jastrzębski, Janina Kaczyńska, O. Kowal-Bielecka, E. Kucharz, J. Kuś, B. Kuźnar-Kamińska, B. Kwiatkowska, R. Langfort, K. Lewandowska, B. Maćkiewicz, S. Majewski, J. Makowska, J. Miłkowska-Dymanowska, E. Puścińska, A. Siemińska, M. Sobiecka, Renata Soroka-Dąda, M. Szołkowska, E. Wiatr, D. Ziora, P. Śliwiński","doi":"10.3390/arm90050052","DOIUrl":"https://doi.org/10.3390/arm90050052","url":null,"abstract":"Highlights The working group of the Polish Respiratory Society (PTChP) developed guidelines for diagnosis and treatment of PF-ILD. What are the main findings? A multidisciplinary team should be involved in the diagnosis and treatment of progressive pulmonary fibrosis. Nintedanib alone or in combination with immunomodulatory drugs is recommended for the treatment of PF-ILD, especially when an earlier solely immunomodulatory treatment was ineffective. What are the implications of the main finding? This document is a guide for Polish medical personnel involved in the diagnosis and treatment of PF-ILD. The guidelines will serve as an aid for healthcare organizers in Poland on how to optimize the diagnostic and therapeutic processes for ILD and improve the access of patients to modern therapy. Abstract The recommendations were developed as answers to previously formulated questions concerning everyday diagnostic and therapeutic challenges. They were developed based on a review of the current literature using the GRADE methodology. The experts suggest that PF-ILD be diagnosed based on a combination of different criteria, such as the aggravation of symptoms, progression of radiological lesions, and worsening of lung function test parameters. The experts recommend a precise diagnosis of an underlying disease, with serological testing for an autoimmune disease always being included. The final diagnosis should be worked out by a multidisciplinary team (MDT). Patients with an interstitial lung disease other than IPF who do not meet the criteria for the progressive fibrosis phenotype should be monitored for progression, and those with systemic autoimmune diseases should be regularly monitored for signs of interstitial lung disease. In managing patients with interstitial lung disease associated with autoimmune diseases, an opinion of an MDT should be considered. Nintedanib rather than pirfenidon should be introduced in the event of the ineffectiveness of the therapy recommended for the treatment of the underlying disease, but in some instances, it is possible to start antifibrotic treatment without earlier immunomodulatory therapy. It is also admissible to use immunomodulatory and antifibrotic drugs simultaneously. No recommendations were made for or against termination of anti-fibrotic therapy in the case of noted progression during treatment of a PF-ILD other than IPF. The experts recommend that the same principles of non-pharmacological and palliative treatment and eligibility for lung transplantation should be applied to patients with an interstitial lung disease other than IPF with progressive fibrosis as in patients with IPF.","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47873170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts ICS/Ultra LABA治疗阻塞性气道疾病:印度专家的共识
IF 1.8 Q3 Medicine Pub Date : 2022-09-29 DOI: 10.3390/arm90050051
R. Dhar, D. Talwar, P. James, A. Mishra, Judo Vachaparambil, Saiprasad Patil, Nishtha Khatri, S. Bhagat, H. Barkate
Highlights What are the main findings? FF/Vi is an effective choice for patients who are uncontrolled on their current Asthma treatment and also for controlled Asthma patients. SABA or ICS/SABA can be a viable reliever option when personalizing treatment for appropriate sets of patients with FF/Vi. What is the implication of the main finding? FF/Vi offers a definitive advantage in terms of treatment adherence and compliance benefit as compared to the conventional ICS/LABAs. Adding LAMA to FF/Vi (100/25 μg) in GOLD group D and B COPD patients can be an optimized strategy. Abstract Inhaled corticosteroid and ultra-long-acting beta-agonist (ICS/uLABA) combination is a recent advancement in the armamentarium against obstructive airways diseases (OADs). The combination of ICS/uLABA has several advantages, creating a favorable landscape for its utilization. Fluticasone furoate/vilanterol trifenatate (FF/Vi) is one such example of an ICS/uLABA. It offers several benefits from both drugs, such as a convenient once daily dosing schedule; high lipophilicity; high receptor affinity of fluticasone furoate along with high functional selectivity and a quick onset of action of vilanterol. However, the Global Initiative for Asthma (GINA) as well as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines do not clearly define the positioning of ICS/uLABA compared to conventional ICS/LABAs. There are a few areas of uncertainty especially around the appropriate reliever strategy with ICS/uLABA in Asthma. The current consensus was planned with a group of Indian pulmonology experts to provide more clarity on the potential use of FF/Vi in Asthma and COPD. The clinical statements highlighted in this consensus manuscript address crucial clinical questions revolving around the efficacy and safety of FF/Vi as compared to conventional ICS/LABAs and identify the ideal patient profile for its use. This consensus paper also sheds light upon the appropriate reliever to be used along with FF/Vi in Asthma and the utilization of FF/Vi-based triple therapy in OADs. Expert recommendations mentioned in this paper will serve as guidance to pulmonologists as well as consultant physicians who are involved in providing care to OAD patients and will help them weigh the various factors that need to be taken into account while prescribing ICS/uLABA combination.
亮点主要发现是什么?FF/Vi是目前哮喘治疗不受控制的患者以及哮喘控制患者的有效选择。当对合适的FF/Vi患者进行个性化治疗时,SABA或ICS/SABA可能是一种可行的缓解方案。主要发现的含义是什么?与传统的ICS/LBA相比,FF/Vi在治疗依从性和依从性方面提供了决定性的优势。在GOLD组和B组COPD患者的FF/Vi(100/25μg)中添加LAMA可以是一种优化的策略。摘要吸入皮质类固醇和超长效β-激动剂(ICS/uLABA)联合用药是治疗阻塞性呼吸道疾病(OAD)的最新进展。ICS/uLABA的组合有几个优点,为其利用创造了有利的环境。糠酸氟替卡松/三丙酸维拉托醇(FF/Vi)是ICS/uLABA的一个这样的例子。它提供了两种药物的几个好处,例如方便的每日一次给药计划;高亲脂性;糠酸氟替卡松的高受体亲和力以及高功能选择性和维拉洛尔的快速起效。然而,全球哮喘倡议(GINA)和全球慢性阻塞性肺病倡议(GOLD)指南并没有明确定义ICS/uLABA与传统ICS/LLABA相比的定位。有一些领域存在不确定性,尤其是在ICS/uLABA治疗哮喘的适当缓解策略方面。目前的共识是与一组印度肺科专家计划达成的,目的是进一步明确FF/Vi在哮喘和COPD中的潜在用途。这份共识手稿中强调的临床声明解决了围绕FF/Vi与传统ICS/LBA相比的疗效和安全性的关键临床问题,并确定了其使用的理想患者概况。这篇共识论文还阐明了在哮喘中与FF/Vi一起使用的合适的缓解剂,以及基于FF/Vi的三联疗法在OAD中的应用。本文中提到的专家建议将为参与为OAD患者提供护理的肺科医生和顾问医生提供指导,并将帮助他们权衡在开具ICS/uLABA组合处方时需要考虑的各种因素。
{"title":"ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts","authors":"R. Dhar, D. Talwar, P. James, A. Mishra, Judo Vachaparambil, Saiprasad Patil, Nishtha Khatri, S. Bhagat, H. Barkate","doi":"10.3390/arm90050051","DOIUrl":"https://doi.org/10.3390/arm90050051","url":null,"abstract":"Highlights What are the main findings? FF/Vi is an effective choice for patients who are uncontrolled on their current Asthma treatment and also for controlled Asthma patients. SABA or ICS/SABA can be a viable reliever option when personalizing treatment for appropriate sets of patients with FF/Vi. What is the implication of the main finding? FF/Vi offers a definitive advantage in terms of treatment adherence and compliance benefit as compared to the conventional ICS/LABAs. Adding LAMA to FF/Vi (100/25 μg) in GOLD group D and B COPD patients can be an optimized strategy. Abstract Inhaled corticosteroid and ultra-long-acting beta-agonist (ICS/uLABA) combination is a recent advancement in the armamentarium against obstructive airways diseases (OADs). The combination of ICS/uLABA has several advantages, creating a favorable landscape for its utilization. Fluticasone furoate/vilanterol trifenatate (FF/Vi) is one such example of an ICS/uLABA. It offers several benefits from both drugs, such as a convenient once daily dosing schedule; high lipophilicity; high receptor affinity of fluticasone furoate along with high functional selectivity and a quick onset of action of vilanterol. However, the Global Initiative for Asthma (GINA) as well as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines do not clearly define the positioning of ICS/uLABA compared to conventional ICS/LABAs. There are a few areas of uncertainty especially around the appropriate reliever strategy with ICS/uLABA in Asthma. The current consensus was planned with a group of Indian pulmonology experts to provide more clarity on the potential use of FF/Vi in Asthma and COPD. The clinical statements highlighted in this consensus manuscript address crucial clinical questions revolving around the efficacy and safety of FF/Vi as compared to conventional ICS/LABAs and identify the ideal patient profile for its use. This consensus paper also sheds light upon the appropriate reliever to be used along with FF/Vi in Asthma and the utilization of FF/Vi-based triple therapy in OADs. Expert recommendations mentioned in this paper will serve as guidance to pulmonologists as well as consultant physicians who are involved in providing care to OAD patients and will help them weigh the various factors that need to be taken into account while prescribing ICS/uLABA combination.","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46388781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Nasal Nitric Oxide Levels: Improving the Diagnosis of Primary Ciliary Dyskinesia in Puerto Rico. 鼻腔一氧化氮水平:改善波多黎各原发性睫状肌运动障碍的诊断。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-09-26 DOI: 10.3390/arm90050050
Wilfredo De Jesús-Rojas, Francisco Alvarado-Huerta, Jesús M Meléndez-Montañez, José Muñiz-Hernández, Arnaldo Santos-López, Ricardo A Mosquera

Primary Ciliary Dyskinesia (PCD) is a rare genetic disease characterized by motile cilia dysfunction with a prevalence of 1 in 16,309 individuals in Hispanic populations. In Puerto Rico, the prevalence of PCD is unknown. Diagnosis of PCD in Puerto Rico is challenging due to the lack of diagnostic technology. Algorithms for PCD diagnosis include clinical history, genetic testing, ciliary biopsy, and nasal Nitric Oxide (nNO) levels. For the first time, this study successfully implemented and measured the nNO levels in subjects with the RSPH4A (c.921+3_921+6del (intronic)) as a diagnostic tool to complement the current algorithm for PCD diagnosis on the island. The nNO level differentiated homozygous subjects with PCD due to the RSPH4A (c.921+3_921+6del (intronic)) founder mutation compared to healthy gender-age matched controls and subjects with VUS or negative genetic testing for PCD. The acquisition of state-of-the-art diagnostic tools such as nNO positively impacted and expanded our current PCD diagnostic capabilities in Puerto Rico for our founder genetic mutation. The addition of nNO technology promotes earlier disease screening and recognition for patients with PCD on the island. The access to nNO helped us to properly characterize the PCD diagnosis for patients with the RSPH4A (c.921+3_921+6del (intronic)). As a result, our findings will allow us to be part of the national PCD foundation registry and represent Puerto Rican Hispanics in future PCD multicentric clinical trials.

原发性纤毛运动障碍症(PCD)是一种罕见的遗传病,其特点是纤毛运动功能障碍,在西班牙裔人群中的发病率为 1 比 16 309。在波多黎各,PCD 的发病率尚不清楚。由于缺乏诊断技术,在波多黎各诊断 PCD 具有挑战性。PCD 诊断算法包括临床病史、基因检测、睫状体活检和鼻腔一氧化氮(nNO)水平。本研究首次成功实施并测量了 RSPH4A(c.921+3_921+6del(内含子))受试者的 nNO 水平,将其作为一种诊断工具,以补充岛上目前的 PCD 诊断算法。与健康的性别-年龄匹配对照组、VUS 或 PCD 基因检测阴性的受试者相比,nNO 水平可区分因 RSPH4A(c.921+3_921+6del(内含子))创始突变而患有 PCD 的同卵受试者。收购 nNO 等最先进的诊断工具对我们目前在波多黎各针对创始人基因突变的 PCD 诊断能力产生了积极的影响和拓展。nNO 技术的加入促进了对岛上 PCD 患者的早期疾病筛查和识别。nNO 的使用帮助我们对 RSPH4A(c.921+3_921+6del(内含子))患者的 PCD 诊断做出了正确的定性。因此,我们的研究结果将使我们成为全国 PCD 基金会登记处的一部分,并在未来的 PCD 多中心临床试验中代表波多黎各西班牙裔患者。
{"title":"Nasal Nitric Oxide Levels: Improving the Diagnosis of Primary Ciliary Dyskinesia in Puerto Rico.","authors":"Wilfredo De Jesús-Rojas, Francisco Alvarado-Huerta, Jesús M Meléndez-Montañez, José Muñiz-Hernández, Arnaldo Santos-López, Ricardo A Mosquera","doi":"10.3390/arm90050050","DOIUrl":"10.3390/arm90050050","url":null,"abstract":"<p><p>Primary Ciliary Dyskinesia (PCD) is a rare genetic disease characterized by motile cilia dysfunction with a prevalence of 1 in 16,309 individuals in Hispanic populations. In Puerto Rico, the prevalence of PCD is unknown. Diagnosis of PCD in Puerto Rico is challenging due to the lack of diagnostic technology. Algorithms for PCD diagnosis include clinical history, genetic testing, ciliary biopsy, and nasal Nitric Oxide (nNO) levels. For the first time, this study successfully implemented and measured the nNO levels in subjects with the <i>RSPH4A</i> (c.921+3_921+6del (intronic)) as a diagnostic tool to complement the current algorithm for PCD diagnosis on the island. The nNO level differentiated homozygous subjects with PCD due to the <i>RSPH4A</i> (c.921+3_921+6del (intronic)) founder mutation compared to healthy gender-age matched controls and subjects with VUS or negative genetic testing for PCD. The acquisition of state-of-the-art diagnostic tools such as nNO positively impacted and expanded our current PCD diagnostic capabilities in Puerto Rico for our founder genetic mutation. The addition of nNO technology promotes earlier disease screening and recognition for patients with PCD on the island. The access to nNO helped us to properly characterize the PCD diagnosis for patients with the <i>RSPH4A</i> (c.921+3_921+6del (intronic)). As a result, our findings will allow us to be part of the national PCD foundation registry and represent Puerto Rican Hispanics in future PCD multicentric clinical trials.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9313094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adipolin and IL-6 Serum Levels in Chronic Obstructive Pulmonary Disease. 慢性阻塞性肺疾病患者血清脂脂素和IL-6水平
IF 1.8 Q3 Medicine Pub Date : 2022-09-07 DOI: 10.3390/arm90050049
Mohammad Reza Aslani, Mojtaba Amani, Faranak Moghadas, Hassan Ghobadi

Objective(s): One of the adipokines that have insulin-sensitizing properties is adipolin, whose reduced levels have been reported in obesity, oxidative stress, and inflammation. The present study investigated serum interleukin-6 (IL-6) and adipolin levels in chronic obstructive pulmonary disease (COPD) patients. Method: A control case study included 60 COPD patients and 30 healthy subjects in the research and measured adipolin and IL-6 serum levels. In addition, serum adipolin levels in COPD patients were assessed according to the GOLD grade. The relationship between serum adipolin levels and study variables were also analyzed. Results: The results showed reduced adipolin levels in COPD patients compared with healthy individuals (p < 0.001). Furthermore, increased levels of IL-6 were evident in the COPD group compared to the control group (p < 0.001). Adipolin serum levels were positively correlated with PFTs and negatively correlated with IL-6 levels. Conclusion: Decreased adipolin levels enhanced disease severity in COPD patients. It seems that the existence of a significant relationship between adipolin and IL-6 may indicate the role of adipolin in the pathophysiology of COPD.

目的:脂polin是一种具有胰岛素增敏特性的脂肪因子,其水平降低在肥胖、氧化应激和炎症中都有报道。本研究探讨了慢性阻塞性肺疾病(COPD)患者血清白细胞介素-6 (IL-6)和脂脂素水平。方法:选取60例慢性阻塞性肺病患者和30例健康人作为对照,测定血清脂polin和IL-6水平。此外,根据GOLD分级评估COPD患者血清脂polin水平。分析了血清脂脂素水平与研究变量之间的关系。结果:COPD患者的脂脂素水平低于健康人(p < 0.001)。此外,与对照组相比,COPD组IL-6水平明显升高(p < 0.001)。血脂素水平与pft呈正相关,与IL-6水平呈负相关。结论:脂脂素水平降低可提高COPD患者的疾病严重程度。脂polin与IL-6之间存在显著关系,可能提示脂polin在COPD病理生理中的作用。
{"title":"Adipolin and IL-6 Serum Levels in Chronic Obstructive Pulmonary Disease.","authors":"Mohammad Reza Aslani,&nbsp;Mojtaba Amani,&nbsp;Faranak Moghadas,&nbsp;Hassan Ghobadi","doi":"10.3390/arm90050049","DOIUrl":"https://doi.org/10.3390/arm90050049","url":null,"abstract":"<p><p>Objective(s): One of the adipokines that have insulin-sensitizing properties is adipolin, whose reduced levels have been reported in obesity, oxidative stress, and inflammation. The present study investigated serum interleukin-6 (IL-6) and adipolin levels in chronic obstructive pulmonary disease (COPD) patients. Method: A control case study included 60 COPD patients and 30 healthy subjects in the research and measured adipolin and IL-6 serum levels. In addition, serum adipolin levels in COPD patients were assessed according to the GOLD grade. The relationship between serum adipolin levels and study variables were also analyzed. Results: The results showed reduced adipolin levels in COPD patients compared with healthy individuals (p < 0.001). Furthermore, increased levels of IL-6 were evident in the COPD group compared to the control group (p < 0.001). Adipolin serum levels were positively correlated with PFTs and negatively correlated with IL-6 levels. Conclusion: Decreased adipolin levels enhanced disease severity in COPD patients. It seems that the existence of a significant relationship between adipolin and IL-6 may indicate the role of adipolin in the pathophysiology of COPD.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9077577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Climate Change and Respiratory Diseases: Relationship between SARS and Climatic Parameters and Impact of Climate Change on the Geographical Distribution of SARS in Iran. 气候变化与呼吸系统疾病:SARS与气候参数的关系以及气候变化对伊朗SARS地理分布的影响。
IF 1.8 Q3 Medicine Pub Date : 2022-08-29 DOI: 10.3390/arm90050048
Giti Bahrami, Hassan Rafiey, Alireza Shakiba, Mehdi Noroozi, Homeira Sajjadi, Hamed Seddighi

Climate change affects human health, and severe acute respiratory syndrome (SARS) incidence is one of the health impacts of climate change. This study is a retrospective cohort study. Data have been collected from the Iranian Ministry of Health and Medical Education between 17 February 2016 and17 February 2018. The Neural Network Model has been used to predict SARS infection. Based on the results of the multivariate Poisson regression and the analysis of the coexistence of the variables, the minimum daily temperature was positively associated with the risk of SARS in men and women. The risk of SARS has increased in women and men with increasing daily rainfall. According to the result, by changes in bioclimatic parameters, the number of SARS patients will be increased in cities of Iran. Our study has shown a significant relationship between SARS and the climatic variables by the type of climate and gender. The estimates suggest that hospital admissions for climate-related respiratory diseases in Iran will increase by 36% from 2020 to 2050. This study demonstrates one of the health impacts of climate change. Policymakers can control the risks of climate change by mitigation and adaptation strategists.

气候变化影响人类健康,严重急性呼吸系统综合征(SARS)的发病率是气候变化对健康的影响之一。本研究为回顾性队列研究。2016年2月17日至2018年2月17日期间从伊朗卫生和医学教育部收集了数据。神经网络模型已被用于预测SARS感染。多变量泊松回归分析和变量共存分析结果表明,最低日气温与男性和女性的SARS发病风险呈正相关。随着日降雨量的增加,女性和男性患SARS的风险都有所增加。结果显示,由于生物气候参数的变化,伊朗各城市的SARS患者数量将会增加。我们的研究表明,SARS与气候变量之间存在显著的气候类型和性别关系。估计表明,从2020年到2050年,伊朗因气候相关呼吸系统疾病住院的人数将增加36%。这项研究展示了气候变化对健康的影响之一。决策者可以通过减缓和适应战略来控制气候变化的风险。
{"title":"Climate Change and Respiratory Diseases: Relationship between SARS and Climatic Parameters and Impact of Climate Change on the Geographical Distribution of SARS in Iran.","authors":"Giti Bahrami,&nbsp;Hassan Rafiey,&nbsp;Alireza Shakiba,&nbsp;Mehdi Noroozi,&nbsp;Homeira Sajjadi,&nbsp;Hamed Seddighi","doi":"10.3390/arm90050048","DOIUrl":"https://doi.org/10.3390/arm90050048","url":null,"abstract":"<p><p>Climate change affects human health, and severe acute respiratory syndrome (SARS) incidence is one of the health impacts of climate change. This study is a retrospective cohort study. Data have been collected from the Iranian Ministry of Health and Medical Education between 17 February 2016 and17 February 2018. The Neural Network Model has been used to predict SARS infection. Based on the results of the multivariate Poisson regression and the analysis of the coexistence of the variables, the minimum daily temperature was positively associated with the risk of SARS in men and women. The risk of SARS has increased in women and men with increasing daily rainfall. According to the result, by changes in bioclimatic parameters, the number of SARS patients will be increased in cities of Iran. Our study has shown a significant relationship between SARS and the climatic variables by the type of climate and gender. The estimates suggest that hospital admissions for climate-related respiratory diseases in Iran will increase by 36% from 2020 to 2050. This study demonstrates one of the health impacts of climate change. Policymakers can control the risks of climate change by mitigation and adaptation strategists.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33469686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased FluoroDeoxyGlucose (FDG) Avidity Following COVID-19 Vaccination. COVID-19疫苗接种后氟脱氧葡萄糖(FDG)贪婪度增加。
IF 1.8 Q3 Medicine Pub Date : 2022-08-24 DOI: 10.3390/arm90050047
Mo'ath Nassar, Ayman Soubani

A 65-year-old woman presented to the Pulmonary Clinic for evaluation after Positron Emission Tomography/Computed Tomography (PET/CT), which was obtained for assessment of a 12 mm right middle lobe solitary pulmonary nodule [...].

一名65岁女性在接受正电子发射断层扫描/计算机断层扫描(PET/CT)后,到肺部诊所进行评估,以评估右中叶12毫米孤立性肺结节[…]。
{"title":"Increased FluoroDeoxyGlucose (FDG) Avidity Following COVID-19 Vaccination.","authors":"Mo'ath Nassar,&nbsp;Ayman Soubani","doi":"10.3390/arm90050047","DOIUrl":"https://doi.org/10.3390/arm90050047","url":null,"abstract":"<p><p>A 65-year-old woman presented to the Pulmonary Clinic for evaluation after Positron Emission Tomography/Computed Tomography (PET/CT), which was obtained for assessment of a 12 mm right middle lobe solitary pulmonary nodule [...].</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10326754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence to Auto-CPAP and Age: A Stable Condition? Comment on Barroso et al. Influence of Age on Adherence to Auto-CPAP: Experience from a Sleep Center in Portugal. Adv. Respir. Med. 2022, 90, 143-147. 坚持使用自动cpap与年龄:一个稳定的状态?评论巴罗佐等人。年龄对自动cpap坚持的影响:来自葡萄牙睡眠中心的经验。放置和。中华医学杂志,2016,31(3):444 - 444。
IF 1.8 Q3 Medicine Pub Date : 2022-08-18 DOI: 10.3390/arm90040045
Ahmet Cemal Pazarlı, Antonio M Esquinas

We have read with great interest the recent paper published by Barroso et al. [...].

我们饶有兴趣地阅读了Barroso等人最近发表的论文[…]。
{"title":"Adherence to Auto-CPAP and Age: A Stable Condition? Comment on Barroso et al. Influence of Age on Adherence to Auto-CPAP: Experience from a Sleep Center in Portugal. <i>Adv. Respir. Med.</i> 2022, <i>90</i>, 143-147.","authors":"Ahmet Cemal Pazarlı,&nbsp;Antonio M Esquinas","doi":"10.3390/arm90040045","DOIUrl":"https://doi.org/10.3390/arm90040045","url":null,"abstract":"<p><p>We have read with great interest the recent paper published by Barroso et al. [...].</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10321257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Awake Prone-Positioning in Patients on Non-Invasive Ventilation for Management of SARS-CoV-2 Pneumonia: A Systematic Review. 对接受无创通气治疗的 SARS-CoV-2 肺炎患者采取清醒俯卧位:系统回顾。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-08-18 DOI: 10.3390/arm90040046
Geetanjali Tolia Chilkoti, Medha Mohta, Zainab Ahmad, Ashok Kumar Saxena

Introduction: Patients with corona virus disease-19 (COVID-19)-induced acute hypoxemic respiratory failure (AHRF) are often on non-invasive ventilation (NIV) and use of awake prone positioning (PP) may pose concern in terms of feasibility, efficacy and side effects. This systematic review was undertaken to evaluate the feasibility and efficacy of awake PP along with NIV in them.

Materials and methods: A systematic literature search was conducted from the inception of COVID-19 until 15 August 2021. Various factors including feasibility, interface used, outcome, efficacy, side effects and limitations in both intensive care unit (ICU) and Non-ICU setups were noted.

Results: A total of 12 original articles and six case series including 359 patients were involved. Out of it, 40% (n = 122) of patients were in ICU and 60% (n = 237) in Non-ICU areas. Four clinical studies and four case series including 114 patients had evaluated PP along with helmet continuous positive airway pressure (CPAP). All had found PP with helmet CPAP to be feasible and efficacious; however, only one study documented the sustained improvement in oxygenation i.e., 12 h after PP.

Conclusions: The present systematic review observed moderate to serious risk of bias amongst the included studies along with heterogeneity in terms of varied respiratory support amongst patients. However, the use of awake PP in patients on NIV has been found to be feasible and efficacious with no adverse events.

导言:电晕病毒病-19(COVID-19)诱发的急性低氧血症呼吸衰竭(AHRF)患者通常使用无创通气(NIV),而使用清醒俯卧位(PP)可能会在可行性、疗效和副作用方面引起关注。本系统性综述旨在评估清醒俯卧位与 NIV 同时使用的可行性和有效性:从 COVID-19 开始至 2021 年 8 月 15 日进行了系统性文献检索。注意到重症监护室(ICU)和非重症监护室设置中的各种因素,包括可行性、使用的界面、结果、疗效、副作用和局限性:结果:共涉及 12 篇原创文章和 6 个病例系列,包括 359 名患者。其中,40%(122 人)的患者住在重症监护室,60%(237 人)的患者住在非重症监护室。四项临床研究和四项病例系列(包括 114 名患者)对使用头盔式持续气道正压(CPAP)的患者进行了评估。所有研究都发现,使用头盔式持续气道正压(CPAP)的密闭式呼吸机是可行且有效的;但是,只有一项研究记录了密闭式呼吸机使用 12 小时后氧合状况的持续改善:本系统综述观察到,纳入的研究存在中度至严重的偏倚风险,患者的呼吸支持也存在异质性。然而,在使用 NIV 的患者中使用清醒 PP 是可行且有效的,而且没有不良反应。
{"title":"Awake Prone-Positioning in Patients on Non-Invasive Ventilation for Management of SARS-CoV-2 Pneumonia: A Systematic Review.","authors":"Geetanjali Tolia Chilkoti, Medha Mohta, Zainab Ahmad, Ashok Kumar Saxena","doi":"10.3390/arm90040046","DOIUrl":"10.3390/arm90040046","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with corona virus disease-19 (COVID-19)-induced acute hypoxemic respiratory failure (AHRF) are often on non-invasive ventilation (NIV) and use of awake prone positioning (PP) may pose concern in terms of feasibility, efficacy and side effects. This systematic review was undertaken to evaluate the feasibility and efficacy of awake PP along with NIV in them.</p><p><strong>Materials and methods: </strong>A systematic literature search was conducted from the inception of COVID-19 until 15 August 2021. Various factors including feasibility, interface used, outcome, efficacy, side effects and limitations in both intensive care unit (ICU) and Non-ICU setups were noted.</p><p><strong>Results: </strong>A total of 12 original articles and six case series including 359 patients were involved. Out of it, 40% (n = 122) of patients were in ICU and 60% (n = 237) in Non-ICU areas. Four clinical studies and four case series including 114 patients had evaluated PP along with helmet continuous positive airway pressure (CPAP). All had found PP with helmet CPAP to be feasible and efficacious; however, only one study documented the sustained improvement in oxygenation i.e., 12 h after PP.</p><p><strong>Conclusions: </strong>The present systematic review observed moderate to serious risk of bias amongst the included studies along with heterogeneity in terms of varied respiratory support amongst patients. However, the use of awake PP in patients on NIV has been found to be feasible and efficacious with no adverse events.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40440553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Role of Serum Adrenomedullin in Patients with Ventilator Associated Pneumonia. 血清肾上腺髓质素在呼吸机相关性肺炎患者预后中的作用。
IF 1.8 Q3 Medicine Pub Date : 2022-08-18 DOI: 10.3390/arm90040044
Tamer Abdallah Helmy, Haitham Hamdy Tammam, Michael Ebrahim Leuis, Bassem Nashaat Beshey

Objective: Ventilator associated pneumonia is a common type of sepsis that occurs to about 9-27% of all mechanically ventilated patients and 20-50% of them develop septic shock. Several clinical, laboratory, and radiological methods have been used for diagnosing VAP. Adrenomedullin (ADM) has been found to be elevated in the plasma of septic patients. The study aim was to explore the prognostic role of ADM in the VAP patients.

Design: A prospective observational study.

Setting: Intensive Care Department of Alexandria University Hospitals.

Patients: A total of 140 patients with proven VAP after medical ICU admission were consecutively enrolled.

Methods: APACHE II score, SOFA score, CRP, lactate, and serum ADM were measured at day 0 of VAP diagnosis and 5 days later. The results were correlated with the outcomes of patients.

Results: APACHE II, lactate, and serum ADM on day 0 could predict an unfavorable outcome. ADM prediction power was significantly higher than APACHE II and lactate. Day 5 readings of all tested parameters could predict occurrence of the unfavorable outcome. ADM on day 0 showed the highest sensitivity (96.25%).

Conclusions: Serum adrenomedullin when measured at days 0 and 5 of VAP diagnosis may serve as an early predictor of unfavorable outcome.

目的:呼吸机相关性肺炎是一种常见的败血症类型,约占所有机械通气患者的9-27%,其中20-50%发生感染性休克。几种临床、实验室和放射学方法已被用于诊断VAP。脓毒症患者血浆中肾上腺髓质素(ADM)升高。本研究旨在探讨ADM对VAP患者预后的影响。设计:前瞻性观察性研究。地点:亚历山大大学附属医院重症监护室。患者:连续入组140例ICU住院后证实有VAP的患者。方法:分别于VAP诊断第0天和第5天测定APACHEⅱ评分、SOFA评分、CRP、乳酸、血清ADM。结果与患者的预后相关。结果:第0天APACHE II、乳酸和血清ADM可预测不良结果。ADM的预测能力显著高于APACHE II和lactate。第5天所有测试参数的读数可以预测不良结果的发生。ADM在第0天的敏感性最高,为96.25%。结论:在VAP诊断的第0天和第5天测量血清肾上腺髓质素可作为不良预后的早期预测因子。
{"title":"Prognostic Role of Serum Adrenomedullin in Patients with Ventilator Associated Pneumonia.","authors":"Tamer Abdallah Helmy,&nbsp;Haitham Hamdy Tammam,&nbsp;Michael Ebrahim Leuis,&nbsp;Bassem Nashaat Beshey","doi":"10.3390/arm90040044","DOIUrl":"https://doi.org/10.3390/arm90040044","url":null,"abstract":"<p><strong>Objective: </strong>Ventilator associated pneumonia is a common type of sepsis that occurs to about 9-27% of all mechanically ventilated patients and 20-50% of them develop septic shock. Several clinical, laboratory, and radiological methods have been used for diagnosing VAP. Adrenomedullin (ADM) has been found to be elevated in the plasma of septic patients. The study aim was to explore the prognostic role of ADM in the VAP patients.</p><p><strong>Design: </strong>A prospective observational study.</p><p><strong>Setting: </strong>Intensive Care Department of Alexandria University Hospitals.</p><p><strong>Patients: </strong>A total of 140 patients with proven VAP after medical ICU admission were consecutively enrolled.</p><p><strong>Methods: </strong>APACHE II score, SOFA score, CRP, lactate, and serum ADM were measured at day 0 of VAP diagnosis and 5 days later. The results were correlated with the outcomes of patients.</p><p><strong>Results: </strong>APACHE II, lactate, and serum ADM on day 0 could predict an unfavorable outcome. ADM prediction power was significantly higher than APACHE II and lactate. Day 5 readings of all tested parameters could predict occurrence of the unfavorable outcome. ADM on day 0 showed the highest sensitivity (96.25%).</p><p><strong>Conclusions: </strong>Serum adrenomedullin when measured at days 0 and 5 of VAP diagnosis may serve as an early predictor of unfavorable outcome.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40440552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Association between Influenza and COVID-19 Viruses and the Risk of Atherosclerosis: Meta-Analysis Study and Systematic Review. 流感和COVID-19病毒与动脉粥样硬化风险之间的关系:荟萃分析研究和系统评价
IF 1.8 Q3 Medicine Pub Date : 2022-08-12 DOI: 10.3390/arm90040043
Mahsa Jalili, Kourosh Sayehmiri, Nastaran Ansari, Behzad Pourhossein, Maryam Fazeli, Farid Azizi Jalilian

There is a lot of evidence to suggest that patients infected with the COVID-19 and influenza viruses are at risk of atherosclerosis. Additionally, there are heterogeneous studies on the risk of arthrosclerosis in patients infected with the influenza and COVID-19 viruses. We conducted a case−control and cross-sectional study and examined the association between the risk of atherosclerosis, and influenza virus (IV-A and IV-B) and COVID-19 infections in this study. We searched for keywords such as influenza virus, COVID-19 and atherosclerosis in English and Persian in well-known databases such as PubMed, SID, Magiran and Google Scholar. In this study, we analyzed the information using a meta-analysis, the random effect model, the I2 index and STAT (version 11.2). The results from the analysis of ten studies on influenza virus and nine studies on COVID-19 reviewed individually (totaling 6428 samples for influenza virus infections and 10,785 samples for COVID-19 infections) demonstrated a risk of arthrosclerosis in patients with influenza and COVID-19 infections, with an OR (odds ratio) = 0.45 ((95% CI): 0.25 to 0.64) and an OR (odds ratio) = 1.04 ((95% CI): 0.82 to 1.26), respectively. The present study provides new insights into the risk of atherosclerosis in patients infected with the COVID-19 and influenza viruses. Therefore, it seems necessary to consider different strategies for managing and eradicating viral infections among individuals.

大量证据表明,感染新冠病毒和流感病毒的患者有发生动脉粥样硬化的风险。此外,还有关于流感和COVID-19病毒感染患者关节硬化风险的异质性研究。在本研究中,我们进行了一项病例对照和横断面研究,并检查了动脉粥样硬化风险与流感病毒(IV-A和IV-B)和COVID-19感染之间的关系。我们在PubMed、SID、Magiran、Google Scholar等知名数据库中检索流感病毒、COVID-19、动脉粥样硬化等英文和波斯语关键词。在本研究中,我们使用meta分析、随机效应模型、I2指数和STAT (version 11.2)来分析信息。对10项流感病毒研究和9项COVID-19研究(共6428份流感病毒感染样本和10785份COVID-19感染样本)的分析结果显示,流感和COVID-19感染患者存在关节硬化的风险,OR(比值比)分别为0.45 (95% CI): 0.25至0.64)和1.04 (95% CI) = 0.82至1.26)。本研究为COVID-19和流感病毒感染患者动脉粥样硬化的风险提供了新的见解。因此,似乎有必要考虑不同的策略来管理和根除个人之间的病毒感染。
{"title":"Association between Influenza and COVID-19 Viruses and the Risk of Atherosclerosis: Meta-Analysis Study and Systematic Review.","authors":"Mahsa Jalili,&nbsp;Kourosh Sayehmiri,&nbsp;Nastaran Ansari,&nbsp;Behzad Pourhossein,&nbsp;Maryam Fazeli,&nbsp;Farid Azizi Jalilian","doi":"10.3390/arm90040043","DOIUrl":"https://doi.org/10.3390/arm90040043","url":null,"abstract":"<p><p>There is a lot of evidence to suggest that patients infected with the COVID-19 and influenza viruses are at risk of atherosclerosis. Additionally, there are heterogeneous studies on the risk of arthrosclerosis in patients infected with the influenza and COVID-19 viruses. We conducted a case−control and cross-sectional study and examined the association between the risk of atherosclerosis, and influenza virus (IV-A and IV-B) and COVID-19 infections in this study. We searched for keywords such as influenza virus, COVID-19 and atherosclerosis in English and Persian in well-known databases such as PubMed, SID, Magiran and Google Scholar. In this study, we analyzed the information using a meta-analysis, the random effect model, the I2 index and STAT (version 11.2). The results from the analysis of ten studies on influenza virus and nine studies on COVID-19 reviewed individually (totaling 6428 samples for influenza virus infections and 10,785 samples for COVID-19 infections) demonstrated a risk of arthrosclerosis in patients with influenza and COVID-19 infections, with an OR (odds ratio) = 0.45 ((95% CI): 0.25 to 0.64) and an OR (odds ratio) = 1.04 ((95% CI): 0.82 to 1.26), respectively. The present study provides new insights into the risk of atherosclerosis in patients infected with the COVID-19 and influenza viruses. Therefore, it seems necessary to consider different strategies for managing and eradicating viral infections among individuals.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9122269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Advances in respiratory medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1